Dennis E. Saadeh

Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA.

Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN.

Part of Harrow, Inc., Radley Pharmaceuticals, Inc. is a company that manufactures pharmaceutical products. The company is based in Carson, NV.

Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX.

Part of Santen Pharmaceutical Co., Ltd., Santen, Inc. is a company that develops ophthalmic products. The company is based in Emeryville, CA. The company was founded in 1993 by Adrienne L. Graves. Tatsuya Kaihara has been the CEO of the company since 2017.

Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH.

Encore Vision, Inc. operates as an ophthalmology clinic. It offers EV06, an ophthalmic pharmaceutical solution in a conventional eye drop bottle, which includes its proprietary active pharmaceutical ingredient (API). The company is headquartered in Spokane, WA.

KeepYourSight Foundation provides e-health initiative in the fight against blindness. The company is headquartered in united States.

Implandata Ophthalmic Products GmbH develops diagnosis tool for glaucoma therapy. Its technology Pro-IOP is an eye pressure measurement system consists of an implantable micro sensor, responsible for pressure sensing, an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage and a GSM module which can be connected with the hand held device for transfer of measurement data to a database, which can be accessed by the eye doctor in order to get information about the disease status of the patient. The company was founded by Max Georg Ostermeier and Stefan Meyer in January 2010 and is headquartered in Hannover, Germany.

NVasc, Inc. is an early-stage ophthalmology company founded in February 2019 and funded by Kairos Ventures in November 2019. The company is based in Atherton, CA. The company is focused on treating the leading causes of blindness through choroidal and retinal revascularization. The company is planning to manufacture NVB001 that can be used in toxicokinetic studies and in early clinical trials in humans. NVasc has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases.

Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021.

Qlaris Bio, Inc. operates as a biotechnology company. The company was founded by Thurein Htoo and Barbara Wirostko and is headquartered in Wellesley, MA.

Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC.

The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD.

TherOptix, Inc. develops and manufactures drug-eluting contact lens. The company is headquartered in San Francisco, CA.

Ingram Content Group LLC publishes and distributes books. It offers solutions that include physical book distribution, print-on-demand, and digital services. The company was founded in 1964 and is headquartered in La Vergne, TN.

Fortera Federal Credit Union engages in the provision of financial services. It offers personal and business checking and savings accounts, loans, and other banking services. The company was founded in 1954 and is headquartered in Clarksville, TN.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Part of Amplifon SpA, Bausch & Lomb, Inc. /Miracle-Ear Hearing Aid Business/ is an American company that manufactures and markets hearing aids and related products. Bausch & Lomb, Inc. /Miracle-Ear Hearing Aid Business was acquired by Amplifon SpA from Bausch & Lomb, Inc. on August 30, 1999.

Glaucoma Research Foundation provides education services. The non-profit company is based in San Francisco, CA. The company was founded by Adrienne L. Graves. The CEO is Thomas M. Brunner.

Corium LLC is a commercial-stage biopharmaceutical company that specializes in developing and commercializing novel neuroscience therapies. Corium is based in Grand Rapid, MI, and the CEO of the private company is Perry J. Sternberg. The company provides clinicians with important treatment options for patients, their families, and their caregivers.

Corium Pharma Solutions, Inc. is a full-service contract development and manufacturing organization that specializes in novel drug and consumer product delivery technologies. The company is based in an undisclosed location. The American company offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. Corium Pharma Solutions has a track record spanning nearly 30 years and is jointly owned by B-Flexion and Webster Equity Partners. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, Corplex™ and MicroCor®. Mark A. Sirgo has been the CEO of the company since 2023.